DOCSLIB.ORG

BCBSVT Open Formulary Prior Approval List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BCBSVT Open Formulary Prior Approval List BCBSVT Open Formulary Prior Approval List As of: 10/27/2020 Helpful Tip: To search for a specific drug, use the find feature (Ctrl + F) Trade Name Chemical/Biological Name Class Prior Authorization Program FUSILEV LEVOLEUCOVORIN CALCIUM ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS KHAPZORY LEVOLEUCOVORIN ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS LEVOLEUCOVORIN CALCIUM LEVOLEUCOVORIN CALCIUM ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS VISTOGARD URIDINE TRIACETATE ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS ACTHAR CORTICOTROPIN ADRENAL HORMONES HORMONES BELRAPZO BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS BENDAMUSTINE HCL BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS BENDEKA BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS TREANDA BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS DAW (DISPENSE AS WRITTEN) ALL CUSTOM BELVIQ LORCASERIN HCL ANOREXIANTS ANTI‐OBESITY DRUGS BELVIQ XR LORCASERIN HCL ANOREXIANTS ANTI‐OBESITY DRUGS CONTRAVE ER NALTREXONE HCL/BUPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS DIETHYLPROPION HCL DIETHYLPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS DIETHYLPROPION HCL ER DIETHYLPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS LOMAIRA PHENTERMINE HCL ANOREXIANTS ANTI‐OBESITY DRUGS PHENDIMETRAZINE TARTRATE PHENDIMETRAZINE TARTRATE ANOREXIANTS ANTI‐OBESITY DRUGS QSYMIA PHENTERMINE/TOPIRAMATE ANOREXIANTS ANTI‐OBESITY DRUGS SAXENDA LIRAGLUTIDE ANOREXIANTS ANTI‐OBESITY DRUGS ABIRATERONE ACETATE ABIRATERONE ACETATE ANTIANDROGENS ANTINEOPLASTICS ERLEADA APALUTAMIDE ANTIANDROGENS ANTINEOPLASTICS NUBEQA DAROLUTAMIDE ANTIANDROGENS ANTINEOPLASTICS XTANDI ENZALUTAMIDE ANTIANDROGENS ANTINEOPLASTICS YONSA ABIRATERONE ACET,SUBMICRONIZED ANTIANDROGENS ANTINEOPLASTICS ZYTIGA ABIRATERONE ACETATE ANTIANDROGENS ANTINEOPLASTICS DIACOMIT STIRIPENTOL ANTICONVULSANTS CNS DRUGS EPIDIOLEX CANNABIDIOL (CBD) ANTICONVULSANTS CNS DRUGS LYRICA CR PREGABALIN ANTICONVULSANTS UNCLASSIFIED DRUG PRODUCTS BELLADONNA & OPIUM OPIUM/BELLADONNA ALKALOIDS ANTIDIARRHEALS ANALGESICS FASLODEX FULVESTRANT ANTIESTROGENS ANTINEOPLASTICS FULVESTRANT FULVESTRANT ANTIESTROGENS ANTINEOPLASTICS FOLOTYN PRALATREXATE ANTIMETABOLITES ANTINEOPLASTICS ONUREG AZACITADINE ANTIMETABOLITES ANTINEOPLASTICS VIDAZA AZACITIDINE ANTIMETABOLITES ANTINEOPLASTICS GOCOVRI AMANTADINE HCL ANTIPARKINSONISM AGENTS ANTIPARKINSON DRUGS INBRIJA LEVODOPA ANTIPARKINSONISM AGENTS ANTIPARKINSON DRUGS OSMOLEX ER AMANTADINE HCL ANTIPARKINSONISM AGENTS ANTIPARKINSON DRUGS COSENTYX 150MG SECUKINUMAB ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS COSENTYX 300MG SECUKINUMAB ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS ILUMYA TILDRAKIZUMAB‐ASMN ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS ORENCIA ABATACEPT SC INJECTION ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS OTEZLA APREMILAST TABLETS ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS SILIQ BRODALUMAB ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS SKYRIZI (2 SYRINGES) KIT RISANKIZUMAB‐RZAA ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS STELARA USTEKINUMAB ANTIPSORIATIC / ANTISEBORRHEIC IMMUNOSUPPRESSANTS TALTZ AUTOINJECTOR IXEKIZUMAB ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS TALTZ AUTOINJECTOR (2 PACK) IXEKIZUMAB ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS TALTZ AUTOINJECTOR (3 PACK) IXEKIZUMAB ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS TALTZ SYRINGE IXEKIZUMAB ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS TREMFYA GUSELKUMAB ANTIPSORIATIC / ANTISEBORRHEIC SKIN PREPS LEMTRADA ALEMTUZUMAB INJECTION CD52‐DIRECTED CYTOLYTIC MONOCLONAL ANTIBODY MULTIPLE SCLEROSIS ACETAMINOPHEN W/CODEINE ACETAMINOPHEN WITH CODEINE COMBINATION NARCOTIC /ANALGESICS ANALGESICS APADAZ BENZHYDROCODONE/ACETAMINOPHEN COMBINATION NARCOTIC /ANALGESICS ANALGESICS ASCOMP WITH CODEINE CODEINE/BUTALBITAL/ASA/CAFFEIN COMBINATION NARCOTIC /ANALGESICS ANALGESICS ASPIRIN WITH CODEINE ASPIRIN/CODEINE PHOSPHATE COMBINATION NARCOTIC /ANALGESICS ANALGESICS BENZHYDROCODONE‐ACETAMINOPHEN BENZHYDROCODONE/ACETAMINOPHEN COMBINATION NARCOTIC /ANALGESICS ANALGESICS BUTALBITAL/CAFF/APAP/CODEINE BUTALBIT/ACETAMIN/CAFF/CODEINE COMBINATION NARCOTIC /ANALGESICS ANALGESICS DVORAH ACETAMINOPHEN/CAFF/DIHYDROCOD COMBINATION NARCOTIC /ANALGESICS ANALGESICS FIORICET WITH CODEINE BUTALBIT/ACETAMIN/CAFF/CODEINE COMBINATION NARCOTIC /ANALGESICS ANALGESICS HYDROCODONE BIT‐IBUPROFEN HYDROCODONE/IBUPROFEN COMBINATION NARCOTIC /ANALGESICS ANALGESICS HYDROCODONE W/ACETAMINOPHEN HYDROCODONE/ACETAMINOPHEN COMBINATION NARCOTIC /ANALGESICS ANALGESICS LORCET HYDROCODONE/ACETAMINOPHEN COMBINATION NARCOTIC /ANALGESICS ANALGESICS LORCET HD HYDROCODONE/ACETAMINOPHEN COMBINATION NARCOTIC /ANALGESICS ANALGESICS MARGESIC #3 ACETAMINOPHEN WITH CODEINE COMBINATION NARCOTIC /ANALGESICS ANALGESICS NALOCET OXYCODONE HCL/ACETAMINOPHEN COMBINATION NARCOTIC /ANALGESICS ANALGESICS OXYCODONE HCL‐IBUPROFEN IBUPROFEN/OXYCODONE HCL COMBINATION NARCOTIC /ANALGESICS ANALGESICS TYLENOL W/CODEINE ACETAMINOPHEN WITH CODEINE COMBINATION NARCOTIC /ANALGESICS ANALGESICS VUMERITY DIROXIMEL FUMARATE ORAL COPAXONE MISCELLANEOUS NEUROLOGICAL THERAPYMULTIPLE SCLEROSIS ARIPIPRAZOLE FOR EXTENDEDRELEASE INJECTABLE ABILIFY MAINTENA CUSTOM CUSTOM SUSPENSION FOR INTRAMUSCULAR USE APOKYN APOMORPHINE HYDROCHLORIDE INJCTION CUSTOM CUSTOM CIALIS FOR BENIGN PROSTATIC HYPERTROPHY ONLY TADALAFIL CUSTOM CUSTOM COMPOUNDED* MEDICATIONS CUSTOM CUSTOM DISPENSE AS WRITTEN ‐ DAW BRAND‐ NAME DRUGS WITH GENERICS AVAILABLE CUSTOM CUSTOM ENTERAL NUTRITION AND MEDICAL FOOD CUSTOM CUSTOM HIGH DOSE OPIOIDS CUSTOM CUSTOM INNOHEP TINZAPARIN CUSTOM CUSTOM LUTATHERA LUTETIUM LU 177 DOTATATE CUSTOM CUSTOM LUVERIS LUTROPIN ALFA CUSTOM CUSTOM Blue Cross and Blue Shield of Vermont Open Formulary *For compounds costing $300 or more Prior Approval List As of: 10/27/2020 | Rev: 10/27/2020 Trade Name Chemical/Biological Name Class Prior Authorization Program IMMEDIATE RELEASE/ LONG ACTING IN OPIOID NAÏVE OPIOID NAIVE CUSTOM CUSTOM PERSON PEGASYS PEGYLATED INTERFERON ALFA 2A CUSTOM CUSTOM PEG‐INTRON PEGYLATED INTERFERON ALFA 2A CUSTOM CUSTOM PRALUENT ALICROCUMAB CUSTOM CUSTOM PROVENGE SIPULEUCEL‐T CUSTOM CUSTOM REBETOL ROBAVIRIN CUSTOM CUSTOM REPATHA EVOLOCUMAB CUSTOM CUSTOM SEROQUEL QUETIAPINE CUSTOM CUSTOM VIDAZA AZACITIDINE INJECTIONS CUSTOM CUSTOM VIMIZIM ELOSULFASE ALFA CUSTOM CUSTOM VPRIV VELAGLUCERASE ALFA CUSTOM CUSTOM YONDELIS TRABECTEDIN CUSTOM CUSTOM ZOMACTRA HIGH CUSTOM CUSTOM ARANESP DARBOEPOETIN ALFA ERYTHROID STIMULANTS COLONY STIMULATING FACTORS EPOGEN EPOETIN ALFA ERYTHROID STIMULANTS COLONY STIMULATING FACTORS MIRCERA EPOETIN BETA ERYTHROID STIMULANTS COLONY STIMULATING FACTORS REBLOZYL LUSPATERCEPT‐AAMT ERYTHROID STIMULANTS UNCLASSIFIED DRUG PRODUCTS RETACRIT EPOETIN ALFA‐EPBX ERYTHROID STIMULANTS COLONY STIMULATING FACTORS ORILISSA ELAGOLIX SODIUM GONADOTROPIN & RELATED AGENTS HORMONES GENOTROPIN SOMATROPIN GROWTH HORMONES HORMONES NORDITROPIN FLEXPRO SOMATROPIN GROWTH HORMONES HORMONES NUTROPIN AQ NUSPIN SOMATROPIN GROWTH HORMONES HORMONES OMNITROPE SOMATROPIN GROWTH HORMONES HORMONES SAIZEN SOMATROPIN GROWTH HORMONES HORMONES SAIZENPREP SOMATROPIN GROWTH HORMONES HORMONES SEROSTIM SOMATROPIN GROWTH HORMONES HORMONES ZOMACTON SOMATROPIN GROWTH HORMONES HORMONES ZORBTIVE SOMATROPIN GROWTH HORMONES HORMONES AIMOVIG AUTOINJECTOR ERENUMAB‐AOOE HEADACHE THERAPY ANALGESICS AJOVY FREMANEZUMAB‐VFRM HEADACHE THERAPY ANALGESICS EMGALITY GALCANEZUMAB‐GNLM HEADACHE THERAPY ANALGESICS EMGALITY SYRINGE GALCANEZUMAB‐GNLM HEADACHE THERAPY ANALGESICS DOPTELET AVATROMBOPAG MALEATE HEMOSTATICS COLONY STIMULATING FACTORS MULPLETA LUSUTROMBOPAG HEMOSTATICS COLONY STIMULATING FACTORS NPLATE ROMIPLOSTIM HEMOSTATICS COLONY STIMULATING FACTORS WILATE ANTIHEMOPHILIC FACTOR/VWF HEMOSTATICS BLOOD HETLIOZ TASIMELTEON HYPNOTIC AGENTS SEDATIVE/HYPNOTICS ZEPOSIA OZANIMOD IMMUNOMODULATOR MULTIPLE SCLEROSIS GAMIFANT EMAPALUMAB‐LZSG IMMUNOSUPPRESSANT DRUGS IMMUNOSUPPRESSANTS EXTAVIA INTERFERON BETA‐1B INTERFERONS CNS DRUGS PEGASYS PEGINTERFERON ALFA‐2A INTERFERONS ANTIVIRALS PLEGRIDY PEGINTERFERON BETA‐1A INTERFERONS CNS DRUGS REBIF INTERFERON BETA‐1A/ALBUMIN INTERFERONS CNS DRUGS REBIF REBIDOSE INTERFERON BETA‐1A/ALBUMIN INTERFERONS CNS DRUGS AYVAKIT AVAPRITINIB TABLET KINASE INHIBITOR ANTINEOPLASTICS JUXTAPID LOMITAPIDE MESYLATE LIPID LOWERING/CHOLESTEROL CARDIOVASCULAR NEXLETOL BEMPEDOIC ACID ORAL LIPID LOWERING/CHOLESTEROL HYPERLIPIDEMIA NEXLIZET BEMPEDOIC ACID/EZETIMIBE ORAL LIPID LOWERING/CHOLESTEROL HYPERLIPIDEMIA PRALUENT PEN ALIROCUMAB LIPID LOWERING/CHOLESTEROL CARDIOVASCULAR REPATHA PUSHTRONEX EVOLOCUMAB LIPID LOWERING/CHOLESTEROL CARDIOVASCULAR REPATHA SURECLICK EVOLOCUMAB LIPID LOWERING/CHOLESTEROL CARDIOVASCULAR REPATHA SYRINGE EVOLOCUMAB LIPID LOWERING/CHOLESTEROL CARDIOVASCULAR SARCLISA ISATUXIMAB INJECTION MISCELLAENOUS ANTINEOPLASTICS ADCETRIS BRENTUXIMAB INJECTION MISCELLANEOUS ANTINEOPLASTICS ARZERRA OFATUZUMAB INJECTION MISCELLANEOUS ANTINEOPLASTICS BLENREP BELANTAMAB MAFODOTIN‐BLMF MISCELLANEOUS ANTINEOPLASTICS DACOGEN DECITABIN INJECTION MISCELLANEOUS ANTINEOPLASTICS GIVLAARI GIVOSIRAN INJECTION MISCELLANEOUS HEPATOLOGY HALAVEN ERIBULIN MESYLATE INJECTION MISCELLANEOUS ANTINEOPLASTICS TRASTUZUMAB‐PKRB INJECTION FOR INTRAVENOUS HERZUMA MISCELLANEOUS ANTINEOPLASTICS INFUSION KANJINTI TRASTUZUMAB‐ANNS INJECTION MISCELLANEOUS ANTINEOPLASTICS KOSELUGO SELUMETINIB CAPSULES MISCELLANEOUS ANTINEOPLASTICS TRASTUZUMAB‐DKST INJECTION FOR INTRAVENOUS OGIVRI MISCELLANEOUS ANTINEOPLASTICS INFUSION TRASTUZUMAB‐DTTB INJECTION FOR INTRAVENOUS ONTRUZANT MISCELLANEOUS ANTINEOPLASTICS INFUSION PEMAZYRE PEMIGATINIB TABLETS MISCELLANEOUS ANTINEOPLASTICS THIOTEPA INJECTION FOR IV, INTRACAVITARY OR TEPADINE MISCELLANEOUS ANTINEOPLASTICS
Load more

Recommended publications
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • 2018-2019 Targeted Medication Safety Best Practices for Hospitals
    2018-2019 Targeted Medication Safety Best Practices for Hospitals The purpose of the Targeted Medication Safety Best Practices for Hospitals is to identify, inspire, and mobilize widespread, national adoption of consensus-based best practices for specific medication safety issues that continue to cause fatal and harmful errors in patients, despite repeated warnings in ISMP publications. Hospitals can focus their medication safety efforts over the next 2 years on these best practices, which are realistic and have been successfully adopted by numerous organizations. While targeted for the hospital-based setting, some best practices may be applicable to other healthcare settings. The Targeted Medication Safety Best Practices for Hospitals have been reviewed by an external expert advisory panel and approved by the ISMP Board of Trustees. Related issues of the ISMP Medication Safety Alert! are referenced after each best practice. ISMP encourages hospitals that have not implemented the 2016-2017 Targeted Medication Safety Best Practices for Hospitals to do so as a priority, while implementing the 2018-2019 best practices. Organizations need to focus on previous best practices 2, 3, 9 and 11 since these have the lowest implementation rate. Two of the 2016-2017 Targeted Medication Safety Best Practices for Hospitals (number 4 and 7) have been revised for 2018-2019. Best practices number 12 through 14 are new for 2018-2019. www.ismp.org BEST PRACTICE 1: Dispense vinCRIStine (and other vinca alkaloids) in a minibag of a compatible solution and not in a syringe. Rationale: Related ISMP Medication The goal of this best practice is to ensure that vinca alkaloids are Safety Alerts!: administered by the intravenous route only.
    [Show full text]
  • Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 1, 2021 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 7 About this guide ......................................................................................................................................... 7 How to use this guide ................................................................................................................................. 7 Administrative rules and supplemental information .................................................................................. 7 Update information............................................................................................................................................... 8 Effective March 1, 2021 ............................................................................................................................ 8 Substantive updates and new criteria ............................................................................................. 8 Clerical changes ............................................................................................................................
    [Show full text]
  • Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England V14 Changes to Version 13
    MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND V14 CHANGES TO VERSION 13 PUBLISHED APRIL 2019 Changes to v13 Lines removed SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER ADULT TA'S (TA195, TA373, ABATACEPT NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE √ MEDICINES FOR CHILDREN TA375) POLICY) Now covered by comment 8 PAEDIATRIC INDICATIONS (IN AS PER TA455 OR ADULT TA'S (TA130 LINE WITH NHS ENGLAND (replaced by TA375), TA143 (repalced by ADALIMUMAB NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √ MEDICINES FOR CHILDREN TA383), TA146, TA187, TA199, TA329, POLICY) TA392, TA460) Now covered by comment 8 ALBUTREPENONACOG ALFA HAEMOPHILIA B PRODUCTS ON CMU Blood factor products simplified NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 √ FRAMEWORK to blood factor product VIII etc PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) Now covered by comment 8 AS PER BCSH GUIDELINES ANTIHAEMOPHILIC FACTOR/VON
    [Show full text]
  • Wednesday, February 10, 2016 4 P.M
    Wednesday, February 10, 2016 4 p.m. Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Bethany Holderread, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – February 10, 2016 DATE: February 1, 2016 Note: The DUR Board will meet at 4:00p.m. The meeting will be held at 4345 N Lincoln Blvd. Enclosed are the following items related to the February meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Oral Viscous Lidocaine Claims Analysis Update – Appendix B Action Item – Vote to Prior Authorize Duopa™ (Carbidopa/Levodopa Enteral Suspension) and Rytary™ (Carbidopa/Levodopa Extended-Release Capsules) – Appendix C Action Item – Vote to Prior Authorize Cortisporin® and Pediotic® (Neomycin/Polymyxin B/Hydrocortisone Otic) – Appendix D Action Item – Vote to Prior Authorize Migranal® (Dihydroergotamine Nasal Spray) – Appendix E Action Item – Vote to Prior Authorize Strensiq™ (Asfotase Alfa) – Appendix F Action Item – Vote to Prior Authorize Varubi™ (Rolapitant) – Appendix G Action Item – Vote to Prior Authorize Xuriden™ (Uridine Triacetate) – Appendix H Annual Review of Gout Medications and 30-Day Notice to Prior Authorize Mitigare™ (Colchicine Capsules) and Zurampic® (Lesinurad) – Appendix I Annual Review of Seizure Medications and 30-Day Notice to Prior Authorize Spritam® (Levetiracetam) – Appendix J 30-Day Notice to Prior Authorize Solaraze® (Diclofenac Gel) – Appendix K Annual Review of Ulcerative Colitis Medications and 30-Day Notice to Prior Authorize Uceris® (Budesonide Extended-Release Tablets), Uceris® (Budesonide Rectal Foam), and Miscellaneous Mesalamine Products – Appendix L Annual Review of Ocular Allergy Medications and 30-Day Notice to Prior Authorize Pazeo® (Olopatadine Ophthalmic) – Appendix M ORI-4403 • P.O.
    [Show full text]
  • Pegvaliase-Pqpz
    Pharmacy Benefit Coverage Criteria Effective Date………….………….....................12/1/2020 Next Review Date………………………………. 12/1/2021 Coverage Policy Number ................................ P0055 Pegvaliase-pqpz Table of Contents Related Coverage Resources Medical Necessity Criteria ................................... 1 Sapropterin FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 2 General Background ............................................ 3 References .......................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Database for Drug Metabolism and Comparisons, Nicedrug.Ch, Aids
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.28.120782; this version posted June 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Database for drug metabolism and comparisons, NICEdrug.ch, aids discovery and design 2 3 Authors/affiliation 1 1,2,5 1,3,5 4 Homa MohammadiPeyhani , Anush Chiappino-Pepe , Kiandokht Haddadi , Jasmin 1 1,4 1,* 5 Hafner , Noushin Hadadi , Vassily Hatzimanikatis 6 1 7 Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de 8 Lausanne, EPFL, Lausanne, Switzerland 2 9 Present address: Department of Genetics, Harvard Medical School, Boston, Massachusetts, 10 USA 3 11 Present address: Department of Chemical Engineering and Applied Chemistry, University of 12 Toronto, Toronto, Canada 4 13 Present address: Department of Cell Physiology and Metabolism, Université de Genève, 14 Geneva, Switzerland 5 15 These authors contributed equally 16 * 17 Corresponding author: 18 Prof. Vassily Hatzimanikatis 19 Laboratory of Computational Systems Biotechnology (LCSB), École Polytechnique Fédérale de 20 Lausanne (EPFL), CH‐1015 21 Lausanne, Switzerland 22 Email: [email protected] , Phone: +41 (0)21 693 98 70, Fax: +41 (0)21 693 98 75 23 24 Abstract 25 The discovery of a drug requires over a decade of enormous research and financial 26 investments—and still has a high risk of failure. To reduce this burden, we developed the 27 NICEdrug.ch database, which incorporates 250,000 bio-active molecules, and studied their 28 metabolic targets, fate, and toxicity.
    [Show full text]
  • New Drug Approvals and Extended Indications for Infants, Children, and Adolescents Marcia L
    PEDIATRIC PHARMACOTHERAPY Volume 21 Number 11 November 2015 New Drug Approvals and Extended Indications for Infants, Children, and Adolescents Marcia L. Buck, PharmD, FCCP, FPPAG ver the past six months, a number of which slowly releases the drug over time, O significant new drugs have been approved providing up to 13 hours of symptom control. by the Food and Drug Administration (FDA). In The safety and efficacy of the product was addition, several drugs already on the market established in a phase 3 randomized, placebo- have been granted an indication for use in controlled trial in 108 children with ADHD.4 pediatric patients. Following a 5-week open-label dose optimization period, patients were randomized to New Drug Product Approvals treatment (2.5-10 mg) or placebo for a 1-week period. At the end of the week, scores on the Adapalene and Benzoyl Peroxide Swanson, Kotkin, Agler, M-Flynn, and Pelham Epiduo Forte®, a new product containing (SKAMP)-Combined rating scale were adapalene 0.3%, a retinoid, and benzoyl peroxide compared to baseline. The change in scores after 2.5% was approved on July 16, 2015 for the treatment demonstrated a statistically significant treatment of moderate to severe acne in adults improvement throughout the day compared to and children 12 years of age and older.1 The placebo (assessed at 1, 2, 6, 8, 10, 12, and 13 efficacy of the new product was demonstrated in hours post-dose), with a mean change of -8.8 (SE a phase 3 multicenter randomized, double-blind 1.14) in the treated patients and 6.0 (SE 1.19) in trial comparing it to the gel vehicle without the the controls.
    [Show full text]
  • Specialty Pharmacy Program Drug List
    Specialty Pharmacy Program Drug List The Specialty Pharmacy Program covers certain drugs commonly referred to as high-cost Specialty Drugs. To receive in- network benefits/coverage for these drugs, these drugs must be dispensed through a select group of contracted specialty pharmacies or your medical provider. Please call the BCBSLA Customer Service number on the back of your member ID card for information about our contracted specialty pharmacies. All specialty drugs listed below are limited to the retail day supply listed in your benefit plan (typically a 30-day supply). As benefits may vary by group and individual plans, the inclusion of a medication on this list does not imply prescription drug coverage. Please refer to your benefit plan for a complete list of benefits, including specific exclusions, limitations and member cost-sharing amounts you are responsible for such as a deductible, copayment and coinsurance. Brand Name Generic Name Drug Classification 8-MOP methoxsalen Psoralen ACTEMRA SC tocilizumab Monoclonal Antibody/Arthritis ACTHAR corticotropin Adrenocortical Insufficiency ACTIMMUNE interferon gamma 1b Interferon ADCIRCA tadalafil Pulmonary Vasodilator ADEMPAS riociguat Pulmonary Vasodilator AFINITOR everolimus Oncology ALECENSA alectinib Oncology ALKERAN (oral) melphalan Oncology ALUNBRIG brigatinib Oncology AMPYRA ER dalfampridine Multiple Sclerosis APTIVUS tipranavir HIV/AIDS APOKYN apomorphine Parkinson's Disease ARCALYST rilonacept Interleukin Blocker/CAPS ATRIPLA efavirenz-emtricitabine-tenofovir HIV/AIDS AUBAGIO
    [Show full text]
  • Management of 5-Fluorouracil (5FU) Infusion Overdose at BC Cancer
    BC Cancer Agency Management Guidelines Management of 5-fluorouracil (5FU) infusion overdose Rationale: 5-FU is an analog of uracil and acts as a pyrimidine antagonist. It is widely used to treat solid tumors and is often administered via infusion devices at or near its maximum tolerated dose. The common use of infusion devices containing 5FU for infusion over several days increases the possibility of potentially lethal overdoses due to device malfunction, dose calculation errors, device selection errors or misprogramming. Toxicities resulting from delivery of 5FU at greater than the intended dose or dose rate can range from mild to life-threatening depending upon the rate of infusion and total dose delivered. Presently, no standard guidelines exist regarding the definition of a 5FU infusion overdose and the recommended management. This guidance serves as a directive regarding the overdose management for 5FU infusors at the BC Cancer Agency (BCCA). More detailed management information can be found in POISINDEX management of fluorouracil and related agents. Directive: Prescribing medical staff, pharmacy and nursing must ensure that every effort is made to minimize the risk of an error in dose calculation or infusor misprogramming. In the event of a 5FU overdose, appropriate and timely measures to anticipate and implement supportive management of patients at risk for severe 5FU toxicity should be implemented per the procedures outlines below. Anticipated toxicities of 5FU can include but are not limited to myelosuppression, nausea, vomiting, stomatitis, diarrhea, ileus, and ileitis. Less common but severe effects can include hepatotoxicity, cardiogenic pulmonary edema, seizures, shock, gastrointestinal bleeding and perforation. Procedures: For the purposes of this guidance, a 5FU infusor overdose will be empirically defined as administration of 5FU via infusor at greater than or equal to 2 times the intended rate with completed delivery of greater than 50% of the intended total 5FU dose.
    [Show full text]